Related Experiment Videos
Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia
Archives of Disease in Childhood
|July 1, 1985
Insights
Severe neonatal isoimmune thrombocytopenia in an infant was successfully treated with intravenous immunoglobulin therapy. This approach offers an alternative to platelet transfusions for managing this condition.
Area of Science:
- Neonatal immunology
- Hematology
- Perinatal medicine
Background:
- Neonatal isoimmune thrombocytopenia (NI) is a condition where maternal antibodies target fetal platelets.
- Severe NI can lead to serious complications like intracranial hemorrhage.
- Maternal immunization against platelet antigen Pla 1 is a common cause of NI.
Observation:
- An infant presented with severe isoimmune thrombocytopenia.
- The thrombocytopenia was attributed to maternal anti-Pla 1 antibodies.
Findings:
- The infant received intravenous immunoglobulin (IVIG) at a dosage of 400 mg/kg per day for five days.
- This treatment resulted in a successful resolution of the thrombocytopenia.
- The efficacy of IVIG was discussed in comparison to Pla 1 negative platelet transfusions.
Implications:
- Intravenous immunoglobulin is a viable and effective treatment for severe neonatal isoimmune thrombocytopenia.
- This therapeutic strategy provides an alternative to potentially risky platelet transfusions.
- Further research can explore optimal IVIG dosing and long-term outcomes in NI patients.
Abstract:
An infant with severe, isoimmune thrombocytopenia secondary to maternal anti-Pla 1 immunisation was treated successfully by intravenous gammaglobulin (400 mg/kg per day for five days). This treatment compared with Pla 1 negative platelet transfusions is discussed.